Industry News
Pharmaceutical Industry News
Citing blood clot risks, CDC advisers recommend mRNA pandemic vaccines over J&J shot
Citing blood clot risks, CDC advisers recommend mRNA pandemic vaccines over J&J shot esagonowsky Thu, 12/16/2021 - 16:23
Pfizer’s peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analysts
Pfizer's peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analysts kdunleavy Thu, 12/16/2021 - 15:50
Pfizer’s peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analysts
Pfizer's peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analysts kdunleavy Thu, 12/16/2021 - 15:50
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst aliu Thu, 12/16/2021 - 11:31
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst aliu Thu, 12/16/2021 - 11:31
Regeneron’s COVID antibody loses effectiveness against omicron, so it’s working on a new version
Regeneron's COVID antibody loses effectiveness against omicron, so it's working on a new version kdunleavy Thu, 12/16/2021 - 11:08
Regeneron’s COVID antibody loses effectiveness against omicron, so it’s working on a new version
Regeneron's COVID antibody loses effectiveness against omicron, so it's working on a new version kdunleavy Thu, 12/16/2021 - 11:08
Vifor Pharma sheds finished drug manufacturing biz days after $11.7B sale to CSL
Vifor Pharma sheds finished drug manufacturing biz days after $11.7B sale to CSL jkeenan Thu, 12/16/2021 - 09:42
Vifor Pharma sheds finished drug manufacturing biz days after $11.7B sale to CSL
Vifor Pharma sheds finished drug manufacturing biz days after $11.7B sale to CSL jkeenan Thu, 12/16/2021 - 09:42
A view to brevity: Brand Institute’s clear-eyed approach to naming AbbVie’s new eyesight drug Vuity
A view to brevity: Brand Institute's clear-eyed approach to naming AbbVie's new eyesight drug Vuity badams Thu, 12/16/2021 - 09:21
A view to brevity: Brand Institute’s clear-eyed approach to naming AbbVie’s new eyesight drug Vuity
A view to brevity: Brand Institute's clear-eyed approach to naming AbbVie's new eyesight drug Vuity badams Thu, 12/16/2021 - 09:21
Novartis launches $15B share buyback after huge windfall from Roche stake sale—but M&A is still in the cards
Novartis launches $15B share buyback after huge windfall from Roche stake sale—but M&A is still in the cards aliu Thu, 12/16/2021 - 09:08
Novartis launches $15B share buyback after huge windfall from Roche stake sale—but M&A is still in the cards
Novartis launches $15B share buyback after huge windfall from Roche stake sale—but M&A is still in the cards aliu Thu, 12/16/2021 - 09:08
Lonza teams with Agilent with aim to transform cell therapy manufacturing
Lonza teams with Agilent with aim to transform cell therapy manufacturing jkeenan Thu, 12/16/2021 - 08:44
Lonza teams with Agilent with aim to transform cell therapy manufacturing
Lonza teams with Agilent with aim to transform cell therapy manufacturing jkeenan Thu, 12/16/2021 - 08:44
Biogen hits the gas pedal on Aduhelm confirmatory trial, hoping to deliver results in 2026
Biogen hits the gas pedal on Aduhelm confirmatory trial, hoping to deliver results in 2026 badams Thu, 12/16/2021 - 04:30
As part of $800M investment, Pfizer opens gene therapy facility in NC for early-stage production
As part of $800M investment, Pfizer opens gene therapy facility in NC for early-stage production kdunleavy Thu, 12/16/2021 - 01:52
As part of $800M investment, Pfizer opens gene therapy facility in NC for early-stage production
As part of $800M investment, Pfizer opens gene therapy facility in NC for early-stage production kdunleavy Thu, 12/16/2021 - 01:52
In its old age, Bristol Myers’ Orencia becomes first drug approved for preventing graft-versus-host disease
In its old age, Bristol Myers' Orencia becomes first drug approved for preventing graft-versus-host disease kdunleavy Wed, 12/15/2021 - 15:38
Eli Lilly trots out rosy 2022 projections, sees recent launches driving two-thirds of its business
Eli Lilly trots out rosy 2022 projections, sees recent launches driving two-thirds of its business kdunleavy Wed, 12/15/2021 - 11:30